Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study

This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Disease(CKD) Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King Abdullah University Hospital and Princess Basma Hospital

Irbid, 22110, Jordan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.

Exclusion criteria

Patients with kidney transplantation .
Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
Patients who refused to provide a written informed consent.

Treatment and study plan

Medication reconciliation service

Other

Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.

Primary outcomes

all-cause 90-day readmission

Time frame: 90 days after discharge

The primary outcome in this study was the likelihood of all-cause 90-day readmission as extracted from medical records for both study groups

Sponsors and collaborators

Lead sponsor

Jordan University of Science and Technology

Other

Registry information

Official study title

The Impact of Medication Reconciliation on Discrepancies and All-cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-experimental Study

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Feb 11, 2025
Registry last updated: Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed